Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.

Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. by Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Snippes Vagnone P, Witwer M, Castanheira M and Johnson JR. J. Antimicrob. Chemother.: in press, 2021.

Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles.

Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles. by Castanheira M, Collingsworth TD, Davis AP, Deshpande LM and Pfaller MA. published in Mycoses. in press, 2021.

Characterization of a vga gene variant recovered from a Staphylococcus saprophyticus causing a community-acquired urinary tract infection: Report from the SENTRY Antimicrobial Surveillance Program 2017.

Characterization of a vga gene variant recovered from a Staphylococcus saprophyticus causing a community-acquired urinary tract infection: Report from the SENTRY Antimicrobial Surveillance Program 2017. by Deshpande L, Cantrell L, Romero JR, Carvalhaes C and Sader HS. published in Diagn. Microbiol. Infect. Dis. 2021; 100 (4): 115398

Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019).

Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019). by Carvalhaes CG, Sader HS, Rhomberg PR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 92-100

Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterization of Candida auris detected in a surveillance program.

Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterization of Candida auris detected in a surveillance program. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M. published in Antimicrob. Agents Chemother. 2021; 65 (4): e02031

Molecular characterization of baseline Enterobacterales and Pseudomonas aeruginosa isolates from a Phase 3 nosocomial pneumonia (ASPECT-NP) clinical trial.

Molecular characterization of baseline Enterobacterales and Pseudomonas aeruginosa isolates from a Phase 3 nosocomial pneumonia (ASPECT-NP) clinical trial. by Castanheira M, Johnson MG, Yu B, Huntington JA, Carmelitano P, Bruno C, Rhee EG and Motyl M. published in Antimicrob. Agents Chemother. 2021; 65 (3): e02461

In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains.

In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Parr TR and Castanheira M. published in Antimicrob. Agents Chemother. 2020; 65 (1): e00742

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Sader HS, Carvalhaes CG, Arends SJR, Castanheira M and Mendes RE. published in J. Antimicrob. Chemother. 2021; 76 (3): 659-666

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis.

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis. by Sader HS, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 69-71

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U. S. gram-negative bacterial surveillance isolates (2012-2018).

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U. S. gram-negative bacterial surveillance isolates (2012-2018). by Shortridge D, Carvalhaes CG, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2021; 100 (1): 11530

Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species.

Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. by Sader HS, Carvalhaes CG, Streit JM, Arends SJR and Mendes RE. published in J Glob Antimicrob Resist. 2021; 24: 48-52

Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterisation of Candida auris detected in a surveillance program

Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterisation of Candida auris detected in a surveillance program. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M published in Antimicrob. Agents Chemother.: in press, 2021.

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). by Sader HS, Carvalhaes CG and Mendes RE. published in Int. J. Infect. Dis. 2021; 102: 524-528

In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe.

In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe. by Carvalhaes CG, Duncan LR, Wang W and Sader HS. published in Antimicrob. Agents Chemother. 2020; 64 (11): e01195

Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods.

Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. by Arends SJR, Canino MA, Mendes R, Scangarella-Oman NE and Flamm RK. published in >Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115107

Activity of Novel β-lactamase Inhibitor QPX7728 Combined with β-lactams Against ST258 Klebsiella pneumoniae and ST131 Escherichia coli isolates Producing β-lactamases

Activity of Novel β-lactamase Inhibitor QPX7728 Combined with β-lactams Against ST258 Klebsiella pneumoniae and ST131 Escherichia coli isolates Producing β-lactamases. Lead author Mariana Castanheira. Presented at IDWeek 2020.

Presentation #166

Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia.

Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. by Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, Patel S, Mendes RE and Wenzler E published in Antimicrob. Agents Chemother. 2020; 64 (9): e00559

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): Therapeutic options for multidrug-resistant bacteria.

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): Therapeutic options for multidrug-resistant bacteria. by Sader HS, Castanheira M, Streit JM, Carvalhaes CG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115108

In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains.

In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Parr TR and Castanheira M. published in Antimicrob. Agents Chemother.: in press, 2020.

Ceftaroline Activity against Staphylococcus aureus Isolated from Patients with Infective Endocarditis Worldwide (2010-2019)

Ceftaroline Activity against Staphylococcus aureus Isolated from Patients with Infective Endocarditis Worldwide (2010-2019). Lead author: HS Sader, presented at CHEST 2020, October 18-21, Virtual Conference
Poster #P0447

Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus causing Pneumonia in Patients with and without Cystic Fibrosis.

Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus causing Pneumonia in Patients with and without Cystic Fibrosis. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #347

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #315

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019).

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author Lalitagauri Deshpande. Presented at IDWeek 2020.

Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: Dee Shortridge. Presented at IDWeek 2020.

Poster #1620

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead Author: Lalitagauri Deshpande. Presented at IDWeek2020.

Poster #1589

 

Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms.

Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. by Castanheira M, Doyle TB, Carvalhaes CG, Roth BM, Rhomberg PR and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 98 (1): 115077

Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi

Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1148

Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides

Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides. Primary Author: Helio Sader. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. Lead Author: Helio Sader. Presented at IDWeek 2020.

Poster #1449

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019)

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019). Lead Author: Helio Sader. Presented at IDWeek 2020. 

Presentation #37

Plazomicin Activity against Enterobacterales Isolates Producing Extended-Spectrum β-Lactamases (ESBLs), Carbapenemases, and Aminoglycoside-Modifying Enzymes (AMEs) from United States (US) Hospitals

Plazomicin Activity against Enterobacterales Isolates Producing Extended-Spectrum β-Lactamases (ESBLs), Carbapenemases, and Aminoglycoside-Modifying Enzymes (AMEs) from United States (US) Hospitals. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019. Lead Author: SJ Ryan Arends. Presented at IDWEEK 2020.

Poster #1262

Update on Prevalence of mcr-like Genes Among Enterobacterales in a Global Surveillance Program: Decline in Occurrence of mcr-1.1 and Emergence of mcr-9.1 and mcr-10.1

Update on Prevalence of mcr-like Genes Among Enterobacterales in a Global Surveillance Program: Decline in Occurrence of mcr-1.1 and Emergence of mcr-9.1 and mcr-10.1. Lead Author: Lalitagauri Deshpande. Presented at IDWeek 2020.

Presentation Number: 166.

Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial

Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1169

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Presentation #26

Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019

Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019. Lead author: LR Duncan, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1595

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1589

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019)

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #327

Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US

Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster # 1547

Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019)

Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1463

Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019)

Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #333

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019. Lead author: HS Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1261

In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019)

In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019). Lead author: MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1253

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author: LM Deshpande presented at IDWeek2020, October 21-22, Virtual Conference
Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1620

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019)

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals

Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Lead author: M Castanheira presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1443

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019)

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019). Lead author: H Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #2020

Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates

Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates. Lead author: PR Rhomberg, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1258